new peptide retatrutide (RETA-20) 111mg Research Retatrutide Analog GLP-3RT Research Peptide

Case presentation: We present the case of a 36-year-old man with newly diagnosed type 2 diabetes who developed severe euDKA within days of starting combined therapy with semaglutide and dapagliflozin

For individuals of Asian descent, a BMI 23 kg/m 2 should trigger interventions

Statistical inference for fixed effects used Satterthwaites approximation of degrees of freedom (lmerTest v.3.1.3) and FDR correction (BenjaminiHochberg) was applied across metabolites separately for each fixed-effects term

Grade 2 patients have moderately severe symptoms but no weight loss, and require prokinetic drugs plus antiemetic agents for control